Larimar Therapeutics, Inc. (LRMR) News
Track canonical SquawkNews coverage tagged to LRMR, Larimar Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 7 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Larimar Therapeutics Price Target Announced at $13.00/Share by Leerink Partners
Ratings actions from Benzinga
NEWS | Sep 14, 2026, 09:06 PM UTC
H
LRMR Seeks Accelerated Approval
LRMR submits first module for accelerated approval
EQUITY | Aug 04, 2026, 11:05 AM UTC
L
Larimar Therapeutics Reports Q2 2026 Results
Larimar Therapeutics releases Q2 financial update
EARNINGS | Aug 04, 2026, 11:00 AM UTC
L
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
NEW YORK CITY, NY / / July 5, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Larimar The
EQUITY | Jul 05, 2026, 02:00 PM UTC
L
HC Wainwright & Co. Assumes Larimar Therapeutics at Buy, Announces Price Target of $10
HC Wainwright & Co. analyst Raghuram Selvaraju assumes Larimar Therapeutics (NASDAQ: LRMR ) with a Buy rating and announces Price Target of $10.
EQUITY | Jul 02, 2026, 10:54 AM UTC
H
Why Universe Pharmaceuticals Shares Are Trading Higher By Around 228%; Here Are 20 Stocks Moving Premarket
Shares of Universe Pharmaceuticals Inc (NASDAQ: UPC ) rose sharply in pre-market trading after the company announced it will acquire Best Praise International for $10.75 million. Universe Pharmaceuticals shares jumped 22
RATES | Jun 29, 2026, 11:03 AM UTC
M
Larimar Therapeutics Submits First Module Of Rolling BLA Submission To FDA For Accelerated Approval Of Nomlabofusp; Remaining Modules Expect
Larimar Therapeutics submits first module of rolling BLA for accelerated approval of nomlabofusp.
REGULATION | Jun 29, 2026, 10:32 AM UTC